MCID: LRG014
MIFTS: 38

Large Cell Neuroendocrine Carcinoma

Categories: Cancer diseases, Neuronal diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Large Cell Neuroendocrine Carcinoma

MalaCards integrated aliases for Large Cell Neuroendocrine Carcinoma:

Name: Large Cell Neuroendocrine Carcinoma 11 14 16 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0050872
UMLS 71 C1265996

Summaries for Large Cell Neuroendocrine Carcinoma

Disease Ontology: 11 A lung large cell carcinoma that derives from neuroendocrine cells.

MalaCards based summary: Large Cell Neuroendocrine Carcinoma is related to cervical large cell neuroendocrine carcinoma and lung combined large cell neuroendocrine carcinoma. An important gene associated with Large Cell Neuroendocrine Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways is Neural Stem Cells and Lineage-specific Markers. The drugs Paclitaxel and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and thymus, and related phenotypes are nervous system and growth/size/body region

Related Diseases for Large Cell Neuroendocrine Carcinoma

Diseases related to Large Cell Neuroendocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 694)
# Related Disease Score Top Affiliating Genes
1 cervical large cell neuroendocrine carcinoma 33.1 SYP CHGA
2 lung combined large cell neuroendocrine carcinoma 32.9 SYP ENO2 CHGA ALK
3 thymus large cell carcinoma 32.3 SYP KRT7 KRT5 CHGA
4 ovarian large-cell neuroendocrine carcinoma 32.0 TP53 SYP NCAM1 KRT7 ENO2 CHL1
5 pulmonary large cell neuroendocrine carcinoma 31.7 SYP NKX2-1 NCAM1 NAPSA INSM1 ENO2
6 neuroendocrine carcinoma 31.5 SYP SST NKX2-1 NCAM1 MEN1 KRT7
7 gallbladder adenocarcinoma 31.2 TP53 SYP KRT7 CHGA
8 carcinoid tumors, intestinal 31.0 SYP SST NKX2-1 MEN1 ENO2 CHGA
9 carcinoid syndrome 30.9 SYP SST ENO2 CHGA
10 ampulla of vater cancer 30.9 TP53 KRT7 EGFR
11 obstructive jaundice 30.9 SYP SST KRT7
12 adenocarcinoma 30.8 TP53 NKX2-1 NAPSA KRT7 EGFR CHGA
13 neuroendocrine tumor 30.8 SYP SST NKX2-1 NCAM1 MEN1 INSM1
14 bladder small cell carcinoma 30.7 SYP NCAM1 ENO2
15 tubular adenocarcinoma 30.7 SYP NCAM1 KRT7 ENO2 CHGA
16 breast neuroendocrine neoplasm 30.7 SYP ENO2 CHGA
17 appendix adenocarcinoma 30.6 TP53 SYP KRT7 CHGA
18 multiple endocrine neoplasia, type i 30.6 SYP SST MEN1 CHGA
19 carcinosarcoma 30.6 TP53 SYP KRT7 EGFR
20 mediastinal cancer 30.6 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
21 cystitis cystica 30.5 SYP KRT7
22 serous cystadenocarcinoma 30.5 TP53 NAPSA KRT7
23 colorectal adenocarcinoma 30.5 TP53 KRT7 EGFR
24 cystadenoma 30.5 SYP KRT7 CHGA
25 transitional cell carcinoma 30.4 TP53 KRT7 ENO2 EGFR
26 conn's syndrome 30.4 TP53 SYP SST MEN1 CHGA
27 ectopic cushing syndrome 30.4 SYP SST CHGA
28 small cell cancer of the lung 30.4 TP53 SYP SST NKX2-1 NCAM1 KRT7
29 gastric squamous cell carcinoma 30.4 KRT7 KRT5
30 cervical adenocarcinoma 30.4 TP53 KRT7 INSM1
31 rectum squamous cell carcinoma 30.4 SYP KRT7 KRT5
32 lung cancer susceptibility 3 30.3 TP53 NKX2-1 NAPSA MIR200B KRT7 EGFR
33 ureteral benign neoplasm 30.3 TP53 KRT7
34 endometrial adenocarcinoma 30.3 TP53 MIR200B KRT7 EGFR
35 lung benign neoplasm 30.3 TP53 SYP NKX2-1 NCAM1 KRT7 ENO2
36 adenoma 30.3 TP53 SYP SST MEN1 KRT7 CHGA
37 thymic carcinoma 30.3 SYP NKX2-1 KRT7 KRT5 EGFR
38 small cell carcinoma 30.2 TP53 SYP NKX2-1 NCAM1 NAPSA KRT7
39 bronchus cancer 30.2 KRT7 ENO2 EGFR ALK
40 zollinger-ellison syndrome 30.2 SST MEN1 CHGA
41 gallbladder disease 30.2 TP53 SST KRT7 EGFR
42 papilloma 30.2 TP53 KRT7 KRT5 EGFR
43 rectal benign neoplasm 30.2 TP53 KRT7 EGFR
44 thymoma 30.2 TP53 SYP NKX2-1 KRT7 EGFR
45 mucinous adenocarcinoma 30.2 TP53 NKX2-1 NAPSA KRT7 EGFR ALK
46 papillary adenocarcinoma 30.2 TP53 NKX2-1 NAPSA KRT7 KRT5
47 adenoid squamous cell carcinoma 30.2 TP53 KRT7 KRT5
48 myoma 30.2 TP53 ENO2 EGFR
49 endocrine gland cancer 30.1 SYP SST MIR200B CHGA
50 hyperinsulinemic hypoglycemia 30.1 SYP SST MEN1 CHGA

Graphical network of the top 20 diseases related to Large Cell Neuroendocrine Carcinoma:



Diseases related to Large Cell Neuroendocrine Carcinoma

Symptoms & Phenotypes for Large Cell Neuroendocrine Carcinoma

MGI Mouse Phenotypes related to Large Cell Neuroendocrine Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.17 ALK ASCL1 CHGA CHL1 DLL3 EGFR
2 growth/size/body region MP:0005378 10.07 ALK ASCL1 CHGA CHL1 DLL3 EGFR
3 normal MP:0002873 10.06 ALK ASCL1 EGFR MEN1 MIR7-1 NKX2-1
4 no phenotypic analysis MP:0003012 9.91 ASCL1 CHGA EGFR INSM1 NKX2-1 SST
5 craniofacial MP:0005382 9.81 ASCL1 CHL1 DLL3 EGFR ENO2 INSM1
6 respiratory system MP:0005388 9.61 ALK ASCL1 CHL1 EGFR ENO2 INSM1
7 taste/olfaction MP:0005394 8.92 ASCL1 CHL1 ENO2 INSM1

Drugs & Therapeutics for Large Cell Neuroendocrine Carcinoma

Drugs for Large Cell Neuroendocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605 16129706
3
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
4
Nivolumab Approved Phase 2 946414-94-4
5
Ipilimumab Approved Phase 2 477202-00-9
6
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3 3680
8
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 3003 5743
9 Albumin-Bound Paclitaxel Phase 2
10 Antimitotic Agents Phase 2
11 Tubulin Modulators Phase 2
12 Immunoglobulins Phase 2
13 Immune Checkpoint Inhibitors Phase 2
14 Antibodies, Monoclonal Phase 2
15 Antibodies Phase 2
16 Alkylating Agents Phase 2
17 Antineoplastic Agents, Alkylating Phase 2
18 Antineoplastic Agents, Hormonal Phase 1, Phase 2
19 Hormones Phase 1, Phase 2
20 Hormone Antagonists Phase 1, Phase 2
21 Antiemetics Phase 1, Phase 2
22 glucocorticoids Phase 1, Phase 2
23 Anti-Inflammatory Agents Phase 1, Phase 2
24 Gastrointestinal Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study Unknown status NCT02943798 Phase 2 etoposide plus carboplatin;Paclitaxel plus carboplatin
2 A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung Completed NCT02936323 Phase 1, Phase 2 PEN-221
3 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
4 uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung Recruiting NCT02755675 Phase 2
5 A Phase II, Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung Recruiting NCT05470595 Phase 2 Atezolizumab
6 A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas Active, not recruiting NCT04079712 Phase 2 Cabozantinib S-malate
7 A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors Active, not recruiting NCT03728361 Phase 2 Temozolomide
8 An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors Terminated NCT02709889 Phase 1, Phase 2 Rovalpituzumab tesirine;Dexamethasone
9 A Phase II Trial of Pembrolizumab in Combination With Cisplatin or Carboplatin and Etoposide in Chemotherapy naïve Patients With Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung (Excluding Small Cell) Neuroendocrine Carcinoma Withdrawn NCT03901378 Phase 2 Pembrolizumab
10 A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma Terminated NCT02500914 Phase 1 SC-002
11 Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017) Completed NCT03305133
12 Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix Recruiting NCT04723095
13 A Pilot Feasibility Study of Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma Recruiting NCT04452292

Search NIH Clinical Center for Large Cell Neuroendocrine Carcinoma

Genetic Tests for Large Cell Neuroendocrine Carcinoma

Anatomical Context for Large Cell Neuroendocrine Carcinoma

Organs/tissues related to Large Cell Neuroendocrine Carcinoma:

MalaCards : Lung, Cervix, Thymus, Colon, Lymph Node, Ovary, Prostate

Publications for Large Cell Neuroendocrine Carcinoma

Articles related to Large Cell Neuroendocrine Carcinoma:

(show top 50) (show all 1235)
# Title Authors PMID Year
1
Cervical adenocarcinoma admixing with large cell neuroendocrine carcinoma: A rare case report. 62
35778245 2022
2
Large cell neuroendocrine carcinoma of the floor of mouth and retromolar trigone in association with basaloid squamous cell carcinoma. 62
35523694 2022
3
Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases. 62
36069807 2022
4
De novo large-cell neuroendocrine carcinoma of the prostate: A case report and literature review. 62
36341182 2022
5
Nasopharyngeal Large Cell Neuroendocrine Carcinoma Synchronized With Nasopharyngeal Squamous Cell Carcinoma: A Case Report and Review of Literature. 62
36345713 2022
6
Primary mixed large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder: A case report and literature review. 62
35599132 2022
7
Prognostic significance of YAP1 expression and its association with neuroendocrine markers in resected pulmonary large cell neuroendocrine carcinoma (LCNEC). 62
36103754 2022
8
Patterns of Extrathoracic Metastasis in Lung Cancer Patients. 62
36421344 2022
9
Silent advanced large cell neuroendocrine carcinoma with synchronous adenocarcinoma of the colon: A case report. 62
36438698 2022
10
Combined large-cell neuroendocrine carcinoma and atypical carcinoid of the thymus presenting as ectopic Cushing syndrome. 62
35930234 2022
11
NOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasms. 62
36282054 2022
12
Small Biopsy and Cytology of Pulmonary Neuroendocrine Neoplasms: Brief Overview of Classification, Immunohistochemistry, Molecular Profiles, and World Health Organization Updates. 62
36053019 2022
13
Diagnostic criteria and evolving molecular characterisation of pulmonary neuroendocrine carcinomas. 62
35758205 2022
14
Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series. 62
36366956 2022
15
Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature. 62
35762443 2022
16
Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer. 62
36054506 2022
17
Neuroendocrine tumor G3 of bronchopulmonary origin and its classification. 62
35983917 2022
18
Surgical treatment of intermediate to high grade thymic neuroendocrine neoplasms: case series of five patients and literature review. 62
36388024 2022
19
High-grade mixed neuroendocrine non-neuroendocrine neoplasm of the gastroesophageal junction: A rare case report and review of literature. 62
36308207 2022
20
Atypical Carcinoid Syndrome in a Patient Presenting With Pericarditis and Supraventricular Tachycardia: A Case Report. 62
36381843 2022
21
Large-cell Neuroendocrine Carcinoma of the Lung with Carcinoid Syndrome: A Case Report. 62
36198589 2022
22
Treatment outcome and prognostic analysis of advanced large cell neuroendocrine carcinoma of the lung. 62
36195623 2022
23
Large Cell Neuroendocrine Carcinoma of the Skin/Conjunctiva: A Series of 6 Cases including 1 Combined Case With Squamous Cell Carcinoma. 62
35642978 2022
24
Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report. 62
36064196 2022
25
PD-L1 predicts chemotherapy resistance in large-cell neuroendocrine carcinoma. 62
36205121 2022
26
ASO Author Reflections: Pure and Combined Surgically Resected Large Cell Neuroendocrine Carcinoma of Lung: Could They be Evaluated as a Single Entity? 62
35511389 2022
27
Neuroendocrine Carcinoma of the Esophagus With Liver Metastasis: A Case Report. 62
36225482 2022
28
Risk factors and prognostic factors for pulmonary large cell neuroendocrine carcinoma with brain metastasis. 62
36125491 2022
29
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications. 62
36230576 2022
30
Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1. 62
35696052 2022
31
POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. 62
35760287 2022
32
Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. 62
35543906 2022
33
Complete resection of large-cell neuroendocrine and hepatocellular carcinoma of the liver: A case report. 62
36159537 2022
34
Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma. 62
35544410 2022
35
Large Cell Neuroendocrine Carcinoma of the Lung: A Case Series of 14 Cases. 62
36059356 2022
36
Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab. 62
34817132 2022
37
Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists. 62
35946087 2022
38
Multifocal diffuse large cell neuroendocrine carcinoma of the colon. 62
35975187 2022
39
Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study. 62
36118995 2022
40
Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma. 62
35888627 2022
41
Classifying Pulmonary and Urinary High-grade Neuroendocrine Carcinoma by CK7 Immunohistochemistry. 62
35603802 2022
42
Atezolizumab in combination with carboplatin plus nab-paclitaxel for managing combined large-cell neuroendocrine carcinoma: A case report. 62
35685848 2022
43
Large-cell neuroendocrine carcinoma and combined large-cell neuroendocrine carcinoma: 2 characters in search of an author. 62
35277717 2022
44
Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management. 62
35147672 2022
45
Primary Pure Large-Cell Neuroendocrine Carcinoma of the Ovary: A Rare Case Report. 62
36158286 2022
46
Ampullary Large-Cell Neuroendocrine Carcinoma, a Diagnostic Challenge of a Rare Aggressive Neoplasm: A Case Report and Literature Review. 62
35892508 2022
47
Role of surgery in high-grade neuroendocrine tumors of the lung. 62
36303705 2022
48
Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report. 62
35966332 2022
49
Neuroendocrine Neoplasms of the Larynx: A Clinicopathologic Analysis of 27 Neuroendocrine Tumors and Neuroendocrine Carcinomas. 62
34401980 2022
50
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. 62
35577980 2022

Variations for Large Cell Neuroendocrine Carcinoma

Expression for Large Cell Neuroendocrine Carcinoma

Search GEO for disease gene expression data for Large Cell Neuroendocrine Carcinoma.

Pathways for Large Cell Neuroendocrine Carcinoma

Pathways related to Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.7 SYP NCAM1 ASCL1

GO Terms for Large Cell Neuroendocrine Carcinoma

Biological processes related to Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 noradrenergic neuron development GO:0003358 9.46 INSM1 ASCL1
2 positive regulation of miRNA maturation GO:1903800 9.26 TP53 EGFR
3 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.26 NKX2-1 ASCL1
4 adrenal chromaffin cell differentiation GO:0061104 8.92 INSM1 ASCL1

Sources for Large Cell Neuroendocrine Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....